The global inflammatory bowel disease (IBD) treatment market, valued at approximately USD 20.2 billion in 2022, is set for substantial growth over the next decade. According to new projections, the market is expected to expand at a remarkable Compound Annual Growth Rate (CAGR) of 5.7%, reaching an estimated value of USD 35.1 billion by the end of 2032.
This growth is driven by increased investment and rising expenditures on IBD treatments globally, as well as the growing prevalence of conditions such as Crohn’s disease and ulcerative colitis. From 2017 to 2021, the market experienced a solid growth rate of 4.7%, demonstrating a consistent upward trajectory in response to the increasing demand for advanced medical solutions and personalized therapies.
“As we witness an increase in the global burden of inflammatory bowel diseases, the healthcare sector is responding with innovative treatments, driving both clinical advancements and market growth,” said FMI. “The IBD treatment landscape is evolving with new therapeutic options and a deeper understanding of the disease’s complexities, which is reflected in the growing investments and market projections.”
With promising advancements in biologic treatments, immunosuppressive therapies, and emerging treatments that offer hope for those battling these chronic and often debilitating diseases, the market outlook remains robust.
As the demand for IBD treatments continues to rise, stakeholders, from pharmaceutical companies to healthcare providers, are positioned to benefit from the expanding market opportunities, while continuing to focus on improving patient outcomes and quality of life.
Key Takeaways: Global Inflammatory Bowel Disease (IBD) Treatment Market
- Global Market Growth:
- The global IBD treatment market was valued at USD 20.2 billion in 2022 and is expected to reach USD 35.1 billion by 2032, growing at a CAGR of 5.7% from 2022 to 2032.
- From 2017 to 2021, the market grew at a CAGR of 4.7%.
- USA Market:
- The USA holds the largest market for IBD treatment, projected to reach USD 13.6 billion by 2032.
- Between 2017 and 2021, the USA market grew at a CAGR of 4.7% and is expected to experience a CAGR of 6.4% from 2022 to 2032.
- The USA market presents a USD 6.2 billion absolute dollar opportunity by 2032.
- Over 70,000 new cases of IBD are reported annually in the USA.
- Approved treatments include infliximab, adalimumab, certolizumab pegol, golimumab, and two anti-integrin biologics (Natalizumab, Vedolizumab), along with biosimilars.
- China Market:
- China is the second-largest IBD treatment market, projected to reach USD 4.2 billion by 2032.
- Between 2017 and 2021, the market grew at a CAGR of 5.5%, with a projected CAGR of 6.8% from 2022 to 2032.
- Smoking, due to rising industrialization and lifestyle changes, is a significant factor contributing to IBD cases in China.
- Reistone Biopharma Co. Ltd. is conducting clinical trials for SHR0302, a selective Janus kinase type 1 (JAK1) inhibitor for moderate-to-severe ulcerative colitis.
- United Kingdom Market:
- The IBD treatment market in the UK is expected to grow from USD 842.5 million in 2017 to USD 1.4 billion by 2032, with a CAGR of 4.6% over the next 10 years.
- The treatment of Crohn’s disease, which is the most common form of IBD, is expected to grow at a CAGR of 6% from 2022 to 2032, following a 5% CAGR from 2017 to 2021.
- The absolute dollar opportunity in the UK market is estimated at USD 509 million during the forecast period.
Enhanced Market Demand: Discover Thorough Trends and Insights in Our Complete Report!
Competitive Landscape:
The Inflammatory Bowel Disease (IBD) Treatment market is moderately competitive, with numerous players actively participating. Leading companies in the market include AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Pfizer Inc., and Eli Lilly. To strengthen their market positions, these companies are focusing on product innovation, often through strategic collaborations and partnerships.
Notable recent developments in the IBD Treatment market include:
- May 2022: The Indian Council of Medical Research (ICMR) launched the IBD NutriCare App to improve patient care for inflammatory bowel disease (IBD). The app provides real-time data, alerting dieticians or nutritionists to inaccuracies, enabling quick adjustments to nutritional plans.
- March 2022: AbbVie Inc. received approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (Upadacitinib) as a treatment for individuals with moderately to highly active Ulcerative Colitis.
Key Segments Covered in Inflammatory Bowel Disease Treatment Market Survey:
Inflammatory Bowel Disease Treatment Market by Type:
- Crohn’s Disease
- Ulcerative Colitis
Inflammatory Bowel Disease Treatment Market by Drug Case:
- Amino salicylates
- Corticosteroids
- TNF inhibitors
- IL inhibitors
- Anti-integrin
- JAK inhibitors
- Other Drug Classes
Inflammatory Bowel Disease Treatment Market by Route of Administration:
- Oral
- Injectable
Inflammatory Bowel Disease Treatment Market by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Inflammatory Bowel Disease Treatment Market by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa(MEA)
- Latin America
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube